Диабетическая болезнь почек (ДБП) является широко распространенным заболеванием во всем мире. Она представляет собой одно из наиболее распространенных осложнений сахарного диабета (СД) и является ведущей причиной болезни почек в терминальной стадии болезнипочек (ТСБП). В его развитии участвуют три фундаментальных компонента: гемодинамическая, метаболическая и воспалительная. С клинической точки зрения, постоянная альбуминурия в сочетании с прогрессирующим снижением скорости гломерулярной фильтрации (СКФ) определяет это заболевание. Однако, поскольку эти изменения не являются специфичными для ДБП, необходимо обсудить новые биомаркеры, возникающие в процессе патогенеза заболевания, которые могут помочь в диагностике, наблюдении, лечении и прогнозе заболевания
Диабетическая болезнь почек (ДБП) является широко распространенным заболеванием во всем мире. Она представляет собой одно из наиболее распространенных осложнений сахарного диабета (СД) и является ведущей причиной болезни почек в терминальной стадии болезнипочек (ТСБП). В его развитии участвуют три фундаментальных компонента: гемодинамическая, метаболическая и воспалительная. С клинической точки зрения, постоянная альбуминурия в сочетании с прогрессирующим снижением скорости гломерулярной фильтрации (СКФ) определяет это заболевание. Однако, поскольку эти изменения не являются специфичными для ДБП, необходимо обсудить новые биомаркеры, возникающие в процессе патогенеза заболевания, которые могут помочь в диагностике, наблюдении, лечении и прогнозе заболевания
| № | Муаллифнинг исми | Лавозими | Ташкилот номи |
|---|---|---|---|
| 1 | Shagazatova B.X. | Professor | Tashkent Medical Academy |
| 2 | Rakhimberdiyeva Z.A. | Assistant | Tashkent Medical Academy |
| № | Ҳавола номи |
|---|---|
| 1 | Rico-Fontalvo, J.; Aroca, G.; Cabrales, J.; Daza-Arnedo, R.; Yánez-Rodríguez, T.; Martínez-Ávila, M.C.; Uparella-Gulfo, I.; Raad-Sarabia, M. Molecular mechanisms of diabetic kidney disease. Int. J. Mol. Sci. 2022, 23, 8668. [CrossRef] Jung, C.Y.; Yoo, T.H. Pathophysiologic mechanisms and potential biomarkers in diabetic kidney disease. Diabetes Metab. J. 2022, 46, 181–197. [CrossRef] Jorge, R.F.; Rodrigo, D.A.; Tomas, R.Y.; Maria Cristina, M.A.; Jose, C.; Maria Ximena, C.B.; Amilkar, A.-H.; Isabella, U.-G.; Oscar, V. Inflammation and diabetic kidney disease: New perspectives. J. Biomed. Res. Environ. Sci. 2022, 3, 779–786. [CrossRef] Rico Fontalvo, J.E.; Vázquez Jiménez, L.C.; Rodríguez Yánez, T.; Daza Arnedo, R.; Raad, M.; Montejo Hernandez, J.D.; AbuabaraFranco, E. Diabetic kidney disease: Updating. Rev. Andal. Fac. Med. 2022, 55, 86–98. [CrossRef] Peña, M.J.; Mischak, H.; Heerspink, H.J.L. Proteomics for prediction of disease progression and response to therapy in diabetic kidney disease. Diabetologia 2016, 59, 1819–1831. [CrossRef] [PubMed] Daza-Arnedo, R.; Rico-Fontalvo, J.E.; Pájaro-Galvis, N.; Leal-Martínez, V.; Abuabara-Franco, E.; Raad-Sarabia, M.; MontejoHernández, J.; Cardona-Blanco, M.; Cabrales-Juan, J.; Uparella-Gulfo, I.; et al. Dipeptidyl peptidase-4 inhibitors and diabetic kidney disease: A narrative review. Kidney Med. 2021, 3, 1065–1073. [CrossRef] [PubMed] Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int. 2022, 102 (Suppl. 5), S1–S127. [CrossRef] [PubMed] Fontalvo, J.E.R. Clinical practice guidelines for diabetic kidney disease. Rev. Colomb. Nefrol. 2021, 8, e561. Looker, H.C.; Mauer, M.; Nelson, R.G. Role of kidney biopsies for biomarker discovery in diabetic kidney disease. Adv. Chronic Kidney Dis. 2018, 25, 192–201. [CrossRef] Colhoun, H.M.; Marcovecchio, M.L. Biomarkers of diabetic kidney disease. Diabetologia 2018, 61, 996–1011. [CrossRef] Pereira, P.R.; Carrageta, D.F.; Oliveira, P.F.; Rodrigues, A.; Alves, M.G.; Monteiro, M.P. Metabolomics as a tool for the early diagnosis and prognosis of diabetic kidney disease. Med. Res. Rev. 2022, 42, 1518–1544. [CrossRef] [PubMed] Nowak, N.; Skupien, J.; Niewczas, M.A.; Yamanouchi, M.; Major, M.; Croall, S.; Smiles, A.; Warram, J.; Bonventre, J.; Krolewski, A. Increased plasma kidney injury molecule-1 suggests early progressive renal decline in non-proteinuric patients with type 1 diabetes. Kidney Int. 2016, 89, 459–467. [CrossRef] [PubMed] Haase-Fielitz, A.; Bellomo, R.; Devarajan, P.; Story, D.; Matalanis, G.; Dragun, D.; Haase, M. Novel and conventional serum biomarkers predicting acute kidney injury in adult cardiac surgery—A prospective cohort study. Crit. Care Med. 2009, 37, 553–560. [CrossRef] [PubMed] Kaul, A.; Behera, M.R.; Rai, M.K.; Mishra, P.; Bhaduaria, D.S.; Yadav, S.; Agarwal, V.; Karoli, R.; Prasad, N.; Gupta, A.; et al. Neutrophil Gelatinase-associated Lipocalin: As a Predictor of Early Diabetic Nephropathy in Type 2 Diabetes Mellitus. Indian J. Nephrol. 2018, 28, 53–60. [CrossRef] [PubMed] Barutta, F.; Bellini, S.; Canepa, S.; Durazzo, M.; Gruden, G. Novel biomarkers of diabetic kidney disease: Current status and potential clinical application. Acta Diabetol. 2021, 58, 819–830. [CrossRef] DeFronzo, R.A.; Reeves, W.B.; Awad, A.S. Pathophysiology of diabetic kidney disease: Impact of SGLT2 inhibitors. Nat. Rev. Nephrol. 2021, 17, 319–334. [CrossRef] Tye, S.C.; Denig, P.; Heerspink, H.J.L. Precision medicine approaches for diabetic kidney disease: Opportunities and challenges. Nephrol. Dial. Transplant. Off. Publ. Eur. Dial. Transpl. Assoc.-Eur. Ren. Assoc. 2021, 36 (Suppl. S2), 3–9. [CrossRef] Gupta, A.; Singh, K.; Fatima, S.; Ambreen, S.; Zimmermann, S.; Younis, R.; Krishnan, S.; Rana, R.; Gadi, I.; Schwab, C.; et al. Neutrophil Extracellular Traps Promote NLRP3 Inflammasome Activation and Glomerular Endothelial Dysfunction in Diabetic Kidney Disease. Nutrients 2022, 14, 2965. [CrossRef] Panduru, N.M.; Forsblom, C.; Saraheimo, M.; Thorn, L.; Bierhaus, A.; Humpert, P.M.; Groop, P.-H. Urinary liver-type fatty acid-binding protein and progression of diabetic nephropathy in type 1 diabetes. Diabetes Care 2013, 36, 2077–2083. [CrossRef] Kalantarinia, K.; Awad, A.S.; Siragy, H.M. Urinary and renal interstitial concentrations of TNF-alpha increase prior to the rise in albuminuria in diabetic rats. Kidney Int. 2003, 64, 1208–1213. [CrossRef] Pavkov, M.E.; Nelson, R.G.; Knowler, W.C.; Cheng, Y.; Krolewski, A.S.; Niewczas, M.A. Elevation of circulating TNF receptors 1 and 2 increases the risk of end-stage renal disease in American Indians with type 2 diabetes. Kidney Int. 2015, 87, 812–819. [CrossRef] [PubMed] Sanchez, M.; Roussel, R.; Hadjadj, S.; Moutairou, A.; Marre, M.; Velho, G.; Mohammedi, K. Plasma concentrations of 8-hydroxy20-deoxyguanosine and risk of kidney disease and death in individuals with type 1 diabetes. Diabetologia 2018, 61, 977–984.[CrossRef] Samsu, N. Diabetic Nephropathy: Challenges in Pathogenesis, Diagnosis, and Treatment. BioMed Res. Int. 2021, 2021, 1497449.[CrossRef] [PubMed] Rico Fontalvo, J.E. Diabetic kidney disease: From face to prevention, diagnosis and early intervention. Rev. Colomb. Nefrol. 2020,7, 15–16. Vargas, J.M.L.; Fontalvo, J.E.R.; Rojas, E.M.; Barrios, G.A.C.; Rincón, A.R.; Gomez, A.M.; Martinez, S.; Bernal, L. Effect of pharmacological therapies for glycemic control in patients with type 2 diabetes mellitus on vascular outcomes. Rev. Colomb. Nefrol. 2020, 7, 44–59. Satirapoj, B. Tubulointerstitial Biomarkers for Diabetic Nephropathy. J. Diabetes Res. 2018, 2018, 2852398. [CrossRef] [PubMed] Satirapoj, B.; Adler, S.G. Comprehensive approach to diabetic nephropathy. Kidney Res. Clin. Pract. 2014, 33, 121–131. [CrossRef] Satirapoj, B.; Adler, S.G. Prevalence and Management of Diabetic Nephropathy in Western Countries. Kidney Dis. 2015, 1, 61–70.[CrossRef] Satirapoj, B.; Nast, C.C.; Adler, S.G. Novel insights into the relationship between glomerular pathology and progressive kidney disease. Adv. Chronic Kidney Dis. 2012, 19, 93–100. [CrossRef] Ostermann, M.; Zarbock, A.; Goldstein, S.; Kashani, K.; Macedo, E.; Murugan, R.; Bell, M.; Forni, L.; Guzzi, L.; Joannidis, M.; et al. Recommendations on Acute Kidney Injury Biomarkers from the Acute Disease Quality Initiative Consensus Conference: A Consensus Statement. JAMA Netw. Open 2020, 3, e2019209. [CrossRef] Forsblom, C.; Moran, J.; Harjutsalo, V.; Loughman, T.; Wadén, J.; Tolonen, N.; Thorn, L.; Saraheimo, M.; Gordin, D.; Groop, P.H.; et al. Added value of soluble tumor necrosis factor-α receptor 1 as a biomarker of ESRD risk in patients with type 1 diabetes. Diabetes Care 2014, 37, 2334–2342. [CrossRef] [PubMed] Andrésdóttir, G.; Jensen, M.L.; Carstensen, B.; Parving, H.H.; Hovind, P.; Hansen, T.W.; Rossing, P. Improved prognosis of diabetic nephropathy in type 1 diabetes. Kidney Int. 2015, 87, 417–426. [CrossRef] Thipsawat, S. Early detection of diabetic nephropathy in patients with type 2 diabetes mellitus: A review of the literature. Diabetes Vasc. Dis. Res. 2021, 18, 14791641211058856. [CrossRef] [PubMed] Turk, V.; Stoka, V.; Vasiljeva, O.; Renko, M.; Sun, T.; Turk, B.; Turk, D. Cysteine cathepsins: From structure, function, and regulation to new frontiers. Biochim. Biophys. Acta 2012, 1824, 68–88. [CrossRef] Shi, G.P.; Sukhova, G.K.; Grubb, A.; Ducharme, A.; Rhode, L.H.; Lee, R.T.; Ridker, P.M.; Libby, P.; Chapman, H.A. Cystatin C deficiency in human atherosclerosis and aortic aneurysms. J. Clin. Investig. 1999, 104, 1191–1197. [CrossRef] [PubMed] Xu, Y.; Ding, Y.; Li, X.; Wu, X. Cystatin C is a disease-associated protein subject to multiple regulation. Immunol. Cell Biol. 2015, 93, 442–451. [CrossRef] [PubMed] Dharnidharka, V.R.; Kwon, C.; Stevens, G. Serum cystatin C is superior to serum creatinine as a marker of kidney function: A meta-analysis. Am. J. Kidney Dis. Off. J. Natl. Kidney Found. 2002, 40, 221–226. [CrossRef] Herget-Rosenthal, S.; Marggraf, G.; Hüsing, J.; Göring, F.; Pietruck, F.; Janssen, O.; Phillip, T.; Kribben, A. Early detection of acute renal failure by serum cystatin, C. Kidney Int. 2004, 66, 1115–1122. [CrossRef] Ling, W.; Zhaohui, N.; Ben, H.; Leyi, G.; Jianping, L.; Huili, D.; Jiaqi, Q. Urinary IL-18 and NGAL as early predictive biomarkers in contrast-induced nephropathy after coronary angiography. Nephron Clin. Pract. 2008, 108, c176–c181. [CrossRef] Kim, S.S.; Song, S.H.; Kim, I.J.; Jeon, Y.K.; Kim, B.H.; Kwak, I.S.; Lee, E.K.; Kim, Y.K. Urinary cystatin C and tubular proteinuria predict progression of diabetic nephropathy. Diabetes Care 2013, 36, 656–661. [CrossRef] Jeon, Y.L.; Kim, M.H.; Lee, W.I.; Kang, S.Y. Cystatin C as an early marker of diabetic nephropathy in patients with type 2 diabetes. Clin. Lab. 2013, 59, 1221–1229. [CrossRef] [PubMed] Abbasi, F.; Moosaie, F.; Khaloo, P.; Dehghani Firouzabadi, F.; Fatemi Abhari, S.M.; Atainia, B.; Ardeshir, M.; Nakhjavani, M.; Esteghamati, A. Neutrophil Gelatinase-Associated Lipocalin and Retinol-Binding Protein-4 as Biomarkers for Diabetic Kidney Disease. Kidney Blood Press. Res. 2020, 45, 222–232. [CrossRef] [PubMed] Nauta, F.L.; Boertien, W.E.; Bakker, S.J.L.; van Goor, H.; van Oeveren, W.; de Jong, P.E.; Bilo, H.; Gansevoort, R. Glomerular and tubular damage markers are elevated in patients with diabetes. Diabetes Care 2011, 34, 975–981. [CrossRef] [PubMed] de Carvalho, J.A.M.; Tatsch, E.; Hausen, B.S.; Bollick, Y.S.; Peres, W.; Duarte, M.M.M.F. Urinary kidney injury molecule-1 and neutrophil gelatinase-associated lipocalin as indicators of tubular damage in normoalbuminuric patients with type 2 diabetes. Clin. Biochem. 2016, 49, 59–64. [CrossRef] He, P.; Bai, M.; Hu, J.P.; Dong, C.; Sun, S.; Huang, C. Significance of Neutrophil Gelatinase-Associated Lipocalin as a Biomarker for the Diagnosis of Diabetic Kidney Disease: A Systematic Review and Meta-Analysis. Kidney Blood Press Res. 2020, 45, 497–509. [CrossRef] [PubMed] Sabbisetti, V.S.; Waikar, S.S.; Antoine, D.J.; Smiles, A.; Wang, C.; Ravisankar, A.; Ito, K.; Sharma, S.; Ramadesikan, S.; Lee, M.; et al. Blood kidney injury molecule-1 is a biomarker of acute and chronic kidney injury and predicts progression to ESRD in type I diabetes. J. Am. Soc. Nephrol. 2014, 25, 2177–2186. [CrossRef] |